CN115068384A - 一种快速美白组合物及其应用 - Google Patents
一种快速美白组合物及其应用 Download PDFInfo
- Publication number
- CN115068384A CN115068384A CN202210799036.5A CN202210799036A CN115068384A CN 115068384 A CN115068384 A CN 115068384A CN 202210799036 A CN202210799036 A CN 202210799036A CN 115068384 A CN115068384 A CN 115068384A
- Authority
- CN
- China
- Prior art keywords
- parts
- whitening composition
- whitening
- cosmetic
- quick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000002537 cosmetic Substances 0.000 claims abstract description 49
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 17
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims abstract description 17
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 claims abstract description 14
- 101710200814 Melanotropin alpha Proteins 0.000 claims abstract description 14
- 239000002562 thickening agent Substances 0.000 claims abstract description 13
- 239000005557 antagonist Substances 0.000 claims abstract description 11
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims abstract description 11
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 10
- 239000000018 receptor agonist Substances 0.000 claims abstract description 10
- 239000003906 humectant Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004902 Softening Agent Substances 0.000 claims abstract description 4
- 239000003755 preservative agent Substances 0.000 claims abstract description 4
- 230000002335 preservative effect Effects 0.000 claims abstract description 4
- 108010016731 PPAR gamma Proteins 0.000 claims abstract description 3
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims abstract 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims abstract 2
- 239000002131 composite material Substances 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- RTBWWWVNZWFNBV-SFHVURJKSA-N (2s)-3-phenyl-2-(undec-10-enoylamino)propanoic acid Chemical compound C=CCCCCCCCCC(=O)N[C@H](C(=O)O)CC1=CC=CC=C1 RTBWWWVNZWFNBV-SFHVURJKSA-N 0.000 claims description 7
- 239000003974 emollient agent Substances 0.000 claims description 7
- SBLKVIQSIHEQOF-UPHRSURJSA-N Octadec-9-ene-1,18-dioic-acid Chemical compound OC(=O)CCCCCCC\C=C/CCCCCCCC(O)=O SBLKVIQSIHEQOF-UPHRSURJSA-N 0.000 claims description 6
- 229940116224 behenate Drugs 0.000 claims description 6
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 229940116918 octadecenedioic acid Drugs 0.000 claims description 6
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 5
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims description 2
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 2
- 244000294611 Punica granatum Species 0.000 claims description 2
- 235000014360 Punica granatum Nutrition 0.000 claims description 2
- 240000000513 Santalum album Species 0.000 claims description 2
- 235000008632 Santalum album Nutrition 0.000 claims description 2
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 1
- 241000222666 Boerhavia diffusa Species 0.000 claims 1
- 229940085633 glyceryl linolenate Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- GGJRAQULURVTAJ-PDBXOOCHSA-N rac-1-alpha-linolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-PDBXOOCHSA-N 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 21
- 239000004480 active ingredient Substances 0.000 abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 210000002752 melanocyte Anatomy 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 19
- 102000023984 PPAR alpha Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000008271 cosmetic emulsion Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108091006084 receptor activators Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 102000013814 Wnt Human genes 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000009795 Microphthalmos Diseases 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- PDHAOJSHSJQANO-OWOJBTEDSA-N Oxyresveratrol Chemical compound OC1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 PDHAOJSHSJQANO-OWOJBTEDSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000010478 microphthalmia Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 102000054930 Agouti-Related Human genes 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- 241001517299 Bulbophyllum Species 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000023813 Isia Species 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000916441 Lilium maritimum Species 0.000 description 1
- 101000680845 Luffa aegyptiaca Ribosome-inactivating protein luffin P1 Proteins 0.000 description 1
- 101150004219 MCR1 gene Proteins 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010044210 PPAR-beta Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 1
- 244000302661 Phyllostachys pubescens Species 0.000 description 1
- 235000003570 Phyllostachys pubescens Nutrition 0.000 description 1
- 244000215777 Plumeria rubra Species 0.000 description 1
- 235000013087 Plumeria rubra Nutrition 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 244000261559 Smilax china Species 0.000 description 1
- 235000000485 Smilax china Nutrition 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 1
- 244000178289 Verbascum thapsus Species 0.000 description 1
- 235000010599 Verbascum thapsus Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940084038 salix alba bark extract Drugs 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种快速美白组合物及其应用,涉及化妆品技术领域。本发明提供的快速美白组合物,包括如下组分:按重量份数计,PPAR‑α受体激动剂0.01~1份、PPAR‑γ受体激动剂0.5~4份和α‑MSH拮抗剂0.3~5份;该快速美白组合物应用于制备化妆品,化妆品包括如下组分:按重量份数计,快速美白组合物0.81‑10份、增稠剂0.6份、保湿剂7.5份、乳化剂4份、柔软剂16份、防腐剂1份和水60.9‑69.85份;本发明制备的含有快速美白组合物的化妆品充分考虑了活性成分的透皮吸收率和作用靶点,选择搭配更加侧重于能起到对黑素细胞胞外靶点的调控成分,从而实现快速美白的效果,同时由多种针对黑色素胞外抑制的活性成分组成,具有较强的抗炎效果,快速美白的同时不带来刺激并有缓解皮肤炎症的效果。
Description
技术领域
本发明涉及化妆品技术领域,具体为一种快速美白组合物及其应用。
背景技术
色素沉着问题,包括炎症后色素沉着、日光性色斑和黄褐斑,在人类人群中广泛发生,因此对此有很多相关研究。市面上大部分产品都是通过添加多种美白成分,多方位干扰黑色的形成或加速其分解代谢来达到“协同美白”的效果,但多方位多靶点多路径设计产品也有可能会造成活性成分作用点过于分散而达不到快速美白的效果。
为了保护干细胞不受紫外线的破坏,黑色素细胞生成的黑色素并没有像想象中的均匀分布在整个角质层,而是绝大部分的黑色素都聚集在基底层干细胞里,它们就像一把黑色的小伞覆盖在细胞核上,保护DNA不受紫外线的侵扰。虽然干细胞会不停的分裂出新的角质细胞,但是黑色素并没有均匀分配到子细胞中,更多的黑色素仍选择留在基底层。现有的常规美白产品,更加侧重于选择抑制络氨酸酶生成和活性的活性成分,而与黑素合成酶(如,酪氨酸酶,TRP-1,TRP-2)抑制剂相关的活性成分到达作用靶点需要穿过表皮层(角质层、颗粒层、棘层、基底层)后再穿过黑素细胞膜,因此考虑到活性成分的透皮吸收率和作用靶点,选择搭配更加侧重于能起到对黑素细胞胞外靶点的调控成分,从而实现快速美白的效果,已成为人们更高的追求。
中国专利文献CN111743851A在2020年10月9日公开了一种美白淡斑组合物及其应用,所述美白淡斑组合物包括以下原料:蛋黄油、乳木果油、紫檀芪、维生素E、水解神经酰胺III、橙皮提取物、酵母提取物、欧百里香提取物、白柳树皮提取物、毛蕊花提取物、海百合神经活性美白因子、黄芩提取物、氧化白藜芦醇、乳酸杆菌发酵溶胞产物、传明酸、VC乙基醚、水溶性富勒烯、4-丁基间苯二酚和依克多因,通过将美白活性成分进行组方,从抑制糖化和酪氨酸酶活性两条途径,抑制黑色素的产生,美白淡斑效果显著;中国专利文献CN114099652A在2022年3月1日公开了一种祛痘美白制剂及其制备方法与应用,包括以下重量份原料:丁香4~6份、水蛭3~10份、丹参12~18份、白芨10~15份、白茯苓2~6份、羧甲基壳聚糖6~8份、鸡蛋花提取物1~3份、龙头竹提取物1~5份、十八碳烯二酸1~1.5份、抗坏血酸磷酸酯钠2~3份、木瓜蛋白酶10~15份、连翘苷3~4份以及葡萄籽油10~12份,通过各种成分之间的合理使用与搭配以及特殊工艺制备,协同作用突出,不仅可以高效抑制黑色素的形成,达到美白的效果,同时具有滋润肌肤、杀菌消炎等多种突出效果;中国专利文献CN114099365A在2022年3月1日公开了一种燕窝酸美白亮肤纳米组合物及其制备方法和应用,根据黑色素形成原理,将不同美白机制的活性成分——燕窝酸、十一碳烯酰基苯丙氨酸、肌肽、谷胱甘肽、传明酸和水杨酸共同包载于纳米组合物中,起到协同增加美白效果的功效,其中,燕窝酸、十一碳烯酰基苯丙氨酸、肌肽、谷胱甘肽协同作用,起到阻断黑色素生成的作用;传明酸作为一种蛋白酶抑制剂,起到阻断黑色素转运的作用;水杨酸起到加快角质层脱落和黑色素代谢的作用,从而有效提高活性成分的稳定性、溶解性和美白功效;但这些现有技术的美白组合物更多是通过抑制黑色素的形成和阻断黑色素的转运来达到快速美白功效,并没有考虑活性成分的透皮吸收率和作用靶点,因此选择搭配更加侧重于能起到对黑素细胞胞外靶点的调控成分,具有重大的意义。
发明内容
针对现有技术中存在的问题,本发明提供了一种快速美白组合物及其应用,该快速美白组合物由多种针对黑色素胞外抑制的活性成分组成,提高活性成分的透皮吸收率和选择搭配更加侧重于能起到对黑素细胞胞外靶点的调控成分,具有较强的抗炎效果,快速美白的同时不带来刺激并有快速缓解皮肤炎症的效果。
本发明提供一种快速美白组合物,包括如下组分:按重量份数计,PPAR-α受体激动剂0.01~1份、PPAR-γ受体激动剂0.5~4份和α-MSH拮抗剂0.3~5份。
进一步的,所述PPAR-α激动剂为紫檀芪、檀香提取物、羟基硬脂酸、亚油酸甘油酯和亚麻酸甘油酯中的一种或多种。
进一步的,所述PPAR-γ激动剂为十八碳烯二酸和黄细心根提取物的一种或多种。
进一步的,所述α-MSH拮抗剂为十一碳烯酰基苯丙氨酸、石榴籽提取物和抗坏血酸四异棕榈酸酯中的一种或多种。
进一步的,所述的快速美白组合物,包括如下组分:按重量份数计,紫檀芪0.5份、十八碳烯二酸2.5份和十一碳烯酰基苯丙氨酸2份。
本发明还提供一种含有快速美白组合物的化妆品,包括如下组分:按重量份数计,快速美白组合物0.81-10份、增稠剂0.6份、保湿剂7.5份、复合乳化剂4份、柔润剂16份、防腐剂1份和水60.9-69.85份。
进一步的,所述增稠剂为黄原胶和聚丙烯酸酯交联聚合物-6按照质量比1:5混合而成。
进一步的,所述复合乳化剂为聚甘油-6硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇和聚甘油-6山嵛酸酯按照质量比3:1:1:3混合而成。
进一步的,所述柔润剂为甘油三(乙基己酸)酯、C12-15醇苯甲酸酯、聚二甲基硅氧烷和椰油醇-辛酸酯/癸酸酯中的一组或多种。
进一步的,所述保湿剂为甘油、戊二醇和双甘油中的一种或多种。
进一步的,所述防腐剂为对羟基苯乙酮和1,2-己二醇中的一种或多种。
本发明还提供一种含有快速美白组合物的化妆品的制备办法,包括如下步骤:
S1、按照配比准确称量原料成分;
S2、将增稠剂、保湿剂、水搅拌溶解并加热至80-85℃,得混合溶液;
S3、将复合乳化剂、柔润剂、美白组合物预混后加入混合溶液中,均质搅拌均匀,降温至50℃;
S4、将防腐剂加入,搅拌溶解至均匀,即得化妆品。
另外,还值得注意的是本发明的快速美白机理,具体详细说明如下:
小眼畸形转录相关因子(MITF)是动物机体黑色素合成路径中的关键调控因子,它通过调控动物机体组织中TYR基因的表达量,影响黑色素细胞的发育和分化,从而调节黑色素生成量,是黑色素合成的多个信号通路的靶向基因,是黑色素合成的核心环节。色素沉着控制涉及多个信号途径,最常见的调节黑素形成的信号通路有:cAMP依赖信号通路、Wnt信号通路和ERK信号通路,这三条信号途径都涉及MITF;三条通路中最主要的信号通路是α-MSH/MC1R途径,α-MSH(α-促黑激素)来源于阿黑皮质素原POMC,由角质形成细胞生成并释放,并与黑素细胞黑素皮质激素受体1(MC1R)结合,MC1R激活后可通过MITF来增加刺激黑素生成的信号级联。本发明通过加入α-MSH促黑素的抑制对抗剂,即α-MSH拮抗剂来抑制由α-MSH引发的各个步骤的黑色素生成过程,刺激“AGRP”型蛋白,在控制绑定MCR1受体中起到决定作用,从而实现对MITF的调控;其中,十一碳烯酰基苯丙氨酸是一种α-MSH拮抗剂,可以在α-MSH引发的黑色素形成的各个阶段的生化反应中发挥作用,拦截黑色素生成信号,控制α-MSH与黑色素生成因子的结合,抑制络氨酸酶的活性,进而抑制黑色素的形成,从源头防止黑色素合成;PPARs属于一个核激素受体亚家族,涉及三种不同的PPARs亚型,称为PPARα、PPARβ/δ和PPARγ;PPAR及其相应的配体是治疗各种皮肤病的潜在靶点,包括角质形成细胞分化异常、表皮增生、炎症和通透性屏障功能缺陷在内,其中-α和-γ受体在人类黑素细胞中有所表达,其激活剂可以起到抑制黑素细胞生长的作用;本发明通过添加PPAR-α受体激动剂来调控表皮脂质合成和代谢,在皮肤中,PPAR-α激活已被证明可以调节渗透性屏障稳态、表皮分化、脂质生物合成和炎症基因,本发明通过提供激活后的PPAR-α可显着增加与WNT通路相关的蛋白质,从而实现对MITF的调控;过氧化物酶体增殖激活受体(PPAR-γ)激活剂是影响细胞增殖和色素沉着的最强亚型,激活后的PPAR-γ通过诱导β-链蛋白蛋白酶体降解而抑制Wnt/β-链蛋白通道,进而实现对MITF的调控,其中添加十八碳烯二酸能调节酪氨酸酶基因表达,抑制酪氨酸酶的生成,进而减少黑色素的生成。总而言之,本发明优选能调控小眼畸形转录因子(MITF)表达的活性成分,通过选择α-MSH拮抗剂、PPAR-α受体激活剂或PPAR-γ受体激活剂配合来达到快速美白的效用。
另外,本发明的含有快速美白组合物的化妆品中的活性成分有α-MSH拮抗剂、PPAR-α受体激活剂和PPAR-γ受体激活剂,容易出现水油不相溶,乳液体系不稳定、不均匀的的现象,发明人发现通过加入由聚甘油-6硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇和聚甘油-6山嵛酸酯按照质量比3:1:1:3混合而成的复合乳化剂,可以很好的解决这个问题,其原因可能是:聚甘油-6硬脂酸酯、聚甘油-6山嵛酸酯聚甘油酯作为助乳化剂,有较宽的亲水亲油平衡值,乳化能力强,耐水解好,具有很强的乳化性能,热稳定性和降粘性很强;鲸蜡硬脂醇具有抑制油腻感,稳定化妆品乳胶体的作用;甘油硬脂酸酯的耐水解好,也具有很强的乳化能力,聚甘油-6硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇和聚甘油-6山嵛酸酯按照质量比3:1:1:3混合而成复合乳剂,复配协同作用,亲水能力更好,能降低水的表面张力,形成胶束,改变液滴之间的胶体相互作用大小与范围,使得本发明中的化妆品乳液中的活性物质相容性更好,乳液体系更加稳定,乳化颗粒更利于皮肤渗透,快速美白、去红抗炎症功效效果更显著。
与现有技术相比,本发明的有益效果是:
1.本发明考虑到活性成分的透皮吸收率和作用靶点,选择搭配更加侧重于能起到对黑素细胞胞外靶点的调控成分,从而实现快速美白的效果;
2.本发明所述快速美白组合物由PPAR-α受体激动剂、PPAR-γ受体激动剂和α-MSH拮抗剂这三种针对黑色素胞外抑制的活性成分组成,具有协同效果,可以达到更高、更快的美白效果,快速美白的同时不带来刺激并有快速缓解皮肤炎症的效果;
3.本发明的含有美白组合物的化妆品的多种成分通过科学组方复配而成,快速美白组合物与柔润剂、保湿剂、复合乳化剂、增稠剂等组分配合形成乳液,使得乳液形成稳定的乳化体系,也使得形成的乳液温和、和皮肤的相容性佳、对皮肤和眼睛有较低的刺激性,各组分之间相互协调,使得组合物的美白祛斑的成分更好作用于皮肤,从而使得乳液具有较好的美白、去红抗炎症功效效果;其中复合乳化剂由聚甘油-6硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇和聚甘油-6山嵛酸酯按照质量比3:1:1:3混合而成,增稠剂由黄原胶和聚丙烯酸酯交联聚合物-6按照质量比1:5混合而成,对于含有快速美白组合物的化妆品乳液体系具有很好的稳定性作用,使得乳化颗粒更利于皮肤渗透,快速美白、去红抗炎症功效效果更显著。
附图说明
图1是试验例三中随机抽选2位受试者中的受试者1的VISIA局部标光图及棕色斑图;
图2是试验例三中随机抽选2位受试者中的受试者2的VISIA局部标光图及棕色斑图;
图3是试验例四中随机抽取第1组的1名志愿者1号在2天内拍摄的VISIA红区图。
具体实施方式
本发明下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。实施例中所用到的各种常用化学试剂,均为市售产品。
除非另有定义,本发明所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不用于限制本发明。
本发明的术语“包括”和“具有”以及它们任何变形,意图在于覆盖不排他的包含。例如包含了一系列步骤的过程、方法、装置、产品或设备没有限定于已列出的步骤或模块,而是可选地还包括没有列出的步骤,或可选地还包括对于这些过程、方法、产品或设备固有的其它步骤。
为使本发明的目的、技术方案和优点更加清楚明了,下面结合具体实施方式,对本发明进一步详细说明。应该理解,这些描述只是示例性的,而并非要限制本发明的范围。此外,在以下说明中,省略了对公知结构和技术的描述,以避免不必要地混淆本发明的概念。
以下实施例对本发明做进一步的描述,但该实施例并非用于限制本发明的保护范围。
实施例1-3、对比例1-5的化妆品的制备
含有快速美白组合物的化妆品的实施例,各实施例具体配方如表1所示,对比例1~5与实施例1的差别仅在于化妆品的配方不同,具体配方如表1所示。
表1、实施例1~3和对比例1~5的配方表(重量份)
与实施例3相比,对比例1-3是快速美白组合物的组分发生了改变,其余物质、份数一样;与实施例3相比,对比例4是复合乳化剂的组分比例发生了变化,其余物质、份数一样;与实施例3相比,对比例5是增稠剂的组分比例发生了变化,其余物质、份数一样。
实施例1-3与对比例1-5的化妆品的制备步骤相同,具体为:
S1、按照配比准确称量原料成分;
S2、将增稠剂、保湿剂和水搅拌溶解并加热至80-85℃,得混合溶液;
S3、将复合乳化剂、柔润剂、快速美白组合物预混后加入混合溶液中,均质搅拌均匀,降温至50℃;
S4、将防腐剂加入,搅拌溶解至均匀,即得化妆品。
试验例一、美白自评测试
(1)试验样品:实施例1-3、对比例1-5制备的化妆品;
(2)试验方法:选择17-50岁皮肤有黄褐斑肤色暗沉的受试者,男女各一半,共56人,分为7组,每组8名,受试者随机分组,分别在面部试用实施例1-3和对比例1-5的样品(每组分别使用一种样品);用量为0.2g/次,2次/天(早晚各1次),连续使用一个月,然后自我判断效果,判断标准,分为三大程度:显著变白、稍微变白、无改变或者恶化;
(3)试验结果:
表2、美白自评测试结果
显著变白 | 稍微变白 | 无改变或者恶化 | |
实施例1 | 4 | 3 | 1 |
实施例2 | 3 | 4 | 1 |
实施例3 | 7 | 1 | 0 |
对比例1 | 2 | 3 | 3 |
对比例2 | 1 | 4 | 3 |
对比例3 | 2 | 4 | 2 |
对比例4 | 1 | 3 | 4 |
对比例5 | 1 | 4 | 3 |
由表2结果可知,本发明实施例1-3所制备的美白化妆品作用于面部皮肤后,均具有较好的美白效果,其中实施例3的美白效果最显著,为本发明的最佳实施例;而对比例1-3制备的化妆品,由于缺少快速美白组合物中任意一种组分,产品的美白效果下降,说明本发明提供的快速美白组合物中的各种活性成分复配有协同美白的效果;对比例4制备的化妆品由于乳化剂中的组分没有按照质量比3:1:1:3复配,制得化妆品中的美白活性成分之间不能更好的复配相容,所以作用于皮肤的美白效果也没有那么显著;对比例5制备的化妆品由于增稠剂中的组分没有按照质量比1:5复配,化妆品乳液体系的稳定性不高,活性物质的作用下降,制得的化妆品的美白效果也有所下降。
试验例二、温和功效测试
(1)试验样品:实施例1-3制备的化妆品;
(2)试验依据:根据化妆品安全技术规范2015版,人体皮肤斑贴试验;
(3)阴性对照:对照孔为空白对照(不置任何物质);
(4)试验方法:采用24h封闭式斑贴试验,挑选受试者共96个人,分成3组,每组32个人,每组女25人,男7人,年龄18~59岁,符合受试者志愿入选标准,分别使用实施例1-3制备的化妆品,然后选择面积不超过50mm2,深度约为1mm的合适斑试器,以封闭式斑贴试验方法,将实施例1-3制备的化妆品各0.2g加于斑试器内,将斑试器贴敷于受试者前臂曲侧,用手掌轻压使之均匀地贴敷于皮肤上,24小时后去除受试物,分别于去除后0.5、24、48小时观察皮肤反应,按《化妆品安全技术规范2015》中皮肤封闭型斑贴试验皮肤反应分级标准记录其结果;
表3、皮肤封闭型斑贴试验皮肤反应分级标准
(5)试验结果:
表4、温和测试结果
由表3中数据可知,本发明实施例1-3制备的化妆品的人体皮肤贴斑试验结果都为阴性反应,说明本发明实施例1-3制备的化妆品温和,对皮肤无刺激。
试验例三、美白功效测试
(1)试验样品:实施例3制备的化妆品;
(2)试验方法:筛选10名肤色色沉明显的志愿者,选择面部作为测试部位,测试周期为28天,在使用样品前1天和使用后第14、28天,观察志愿者面部情况;测试前1周为洗脱期,此期间受试者使用不含任何活性物的基础保湿水和保湿乳,在测试期间不能使用其他美白产品;受试者连续28天使用实施例1制备的化妆品样品,每天早晨、晚上睡前洗脸后在面部涂抹样品,涂抹量约为0.2g,然后采用5段法评估:明显改善-稍微改善-不变-稍微恶化-明显恶化,记录各编号情况的人数,并随机抽选2位受试者的VISIA局部标光图及棕色斑图评估使用前后脸部色素的变化情况;
(3)试验结果:
表5、美白功效测试结果
由表5数据可知,使用了实施例3制备的美白化妆品的受试者中,脸部色素明显改善人数有8人,美白效果显著;随机抽选的2位受试者,从附图1可知,受试者1号,在使用完化妆品样品14天(即两周)后,整脸明显提亮,且脸上红色消退,暗沉出肌肤也有明显变白,从棕色斑点图,可明显看到肌肤深层色素沉积程度减少,整脸暗沉均有消退;从附图2可知,受试者2号在两周回访时整体肤色变白,且四周回访有持续改善,从标光图分析,脸颊暗红消退,且额头部位明显变白,从受试者2的棕色斑图更能明显体现其额头部位色沉程度也明显淡化,说明本发明制备的含有快速美白组合物的化妆品的快速美白效果显著。
试验例四、祛红抗炎症功效的测试
(1)试验样品:实施例3、对比例1-5制备的化妆品;
(2)试验方法:筛选60名脸颊有红血丝的志愿者,分成6组,每组10人,分别使用实施例3、对比例1-5制备的化妆品;选择面部作为测试部位,测试周期为14天,在使用样品前1天和使用后第14天,观察志愿者面部红血丝消退情况;测试前1周为洗脱期,此期间受试者使用不含任何活性物的基础保湿水和保湿乳,在测试期间不能使用其他产品;6组受试者连续14天使用化妆品样品,每天早晨、晚上睡前洗脸后在面部涂抹样品,涂抹量约为0.2g,采用5段法评估:明显改善-稍微改善-不变-稍微恶化-明显恶化,记录相关人数;然后随机抽取第1组的1名志愿者1号,每天用ISIA CR拍摄面部,以VISIA红区图评估使用前后脸部红血丝的变化情况;
(3)试验结果:
表6、去红抗炎症功效测试结果
由上表结果可知,10名志愿者使用本发明的实施例3制备的化妆品后的脸部血丝都明显改善,说明本发明制备的含有快速美白组合物的化妆品的祛红抗炎症功效显著;随机抽取的志愿者1号的VISIA红区图参见附图3可知,使用本发明实施例3制备的美白化妆品后,仅2天即可看到脸颊红血丝明显消退且脸部整体红区明显变浅,说明本发明制备的快速美白组合物不仅具有快速美白功效,也具有快速祛红抗炎症功效;而对比例1由于缺乏PPAR-γ受体激动剂,没有去红抗炎症功效;而对比例2-5由于其他活性成分或者是复合乳化剂、增稠剂的比例发生变化,导致化妆品体系稳定性变差,去红抗炎症效果下降明显。
需要说明的是,本说明书中描述的具体特征、结构、材料或者特点可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,在不相互矛盾的情况下,本领域的技术人员可以将本说明书中描述的不同实施例以及不同实施例的特征进行结合和组合。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种快速美白组合物,其特征在于,包括如下组分:按重量份数计,PPAR-α受体激动剂0.01~1份、PPAR-γ受体激动剂0.5~4份和α-MSH拮抗剂0.3~5份。
2.根据权利要求1所述的快速美白组合物,其特征在于,所述PPAR-α激动剂为紫檀芪、檀香提取物、羟基硬脂酸、亚油酸甘油酯和亚麻酸甘油酯中的一种或多种。
3.根据权利要求1所述的快速美白组合物,其特征在于,所述PPAR-γ激动剂为十八碳烯二酸和黄细心根提取物的一种或多种。
4.根据权利要求1所述的快速美白组合物,其特征在于,所述α-MSH拮抗剂为十一碳烯酰基苯丙氨酸、石榴籽提取物和抗坏血酸四异棕榈酸酯中的一种或多种。
5.根据权利要求1所述的快速美白组合物,其特征在于,包括如下组分:按重量份数计,紫檀芪0.5份、十八碳烯二酸2.5份和十一碳烯酰基苯丙氨酸2份。
6.一种含有权利要求1-5任一项所述的快速美白组合物的化妆品,其特征在于,包括如下组分:按重量份数计,快速美白组合物0.81-10份、增稠剂0.6份、保湿剂7.5份、复合乳化剂4份、柔润剂16份、防腐剂1份和水60.9-69.85份。
7.根据权利要求6所述的化妆品,其特征在于,所述增稠剂为黄原胶和聚丙烯酸酯交联聚合物-6按照质量比1:5混合而成。
8.根据权利要求6所述的化妆品,其特征在于,所述复合乳化剂为聚甘油-6硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇和聚甘油-6山嵛酸酯按照质量比3:1:1:3混合而成。
9.根据权利要求6所述的化妆品,其特征在于,所述柔润剂为甘油三(乙基己酸)酯、C12-15醇苯甲酸酯、聚二甲基硅氧烷和椰油醇-辛酸酯/癸酸酯中的一种或多种。
10.一种如权利要求6-9任一项所述的化妆品的制备办法,其特征在于,包括如下步骤:
S1、按照配比准确称量原料成分;
S2、将增稠剂、保湿剂、水搅拌溶解并加热至80-85℃,得混合溶液;
S3、将复合乳化剂、柔润剂、美白组合物预混后加入混合溶液中,均质搅拌均匀,降温至50℃;
S4、将防腐剂加入,搅拌溶解至均匀,即得化妆品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210799036.5A CN115068384A (zh) | 2022-07-08 | 2022-07-08 | 一种快速美白组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210799036.5A CN115068384A (zh) | 2022-07-08 | 2022-07-08 | 一种快速美白组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115068384A true CN115068384A (zh) | 2022-09-20 |
Family
ID=83257899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210799036.5A Pending CN115068384A (zh) | 2022-07-08 | 2022-07-08 | 一种快速美白组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115068384A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115778880A (zh) * | 2023-02-01 | 2023-03-14 | 卡莱丽化妆品有限公司 | 一种脂质体及其制备方法与应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1566168A1 (fr) * | 2004-02-23 | 2005-08-24 | Laboratoires S.V.R. | Compositions dermo-cosmétiques dépigmentantes et leur utilisation |
US20070185038A1 (en) * | 2005-09-30 | 2007-08-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin care actives |
US20100189795A1 (en) * | 2009-01-16 | 2010-07-29 | Neocutis S.A. | Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions |
US20110158922A1 (en) * | 2008-04-15 | 2011-06-30 | Immanence Integrale Dermo Correction Inc. | Skin Care Compositions and Method of Use Thereof |
US20160243015A1 (en) * | 2013-10-25 | 2016-08-25 | Conopco, Inc., D/B/A Unilever | Skin lightening composition |
US20200306172A1 (en) * | 2017-02-06 | 2020-10-01 | Nunii Laboratoire | Depigmenting dermatological and cosmetic compositions |
CN111743785A (zh) * | 2019-03-28 | 2020-10-09 | 珀莱雅化妆品股份有限公司 | 一种具有美白紧致功效的纳米纤维膜及其制备方法 |
WO2021138031A1 (en) * | 2019-12-30 | 2021-07-08 | Rodan & Fields, Llc | Ppar agonist complex and methods of use |
-
2022
- 2022-07-08 CN CN202210799036.5A patent/CN115068384A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1566168A1 (fr) * | 2004-02-23 | 2005-08-24 | Laboratoires S.V.R. | Compositions dermo-cosmétiques dépigmentantes et leur utilisation |
US20070185038A1 (en) * | 2005-09-30 | 2007-08-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin care actives |
US20110158922A1 (en) * | 2008-04-15 | 2011-06-30 | Immanence Integrale Dermo Correction Inc. | Skin Care Compositions and Method of Use Thereof |
US20100189795A1 (en) * | 2009-01-16 | 2010-07-29 | Neocutis S.A. | Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions |
US20160243015A1 (en) * | 2013-10-25 | 2016-08-25 | Conopco, Inc., D/B/A Unilever | Skin lightening composition |
US20200306172A1 (en) * | 2017-02-06 | 2020-10-01 | Nunii Laboratoire | Depigmenting dermatological and cosmetic compositions |
CN111743785A (zh) * | 2019-03-28 | 2020-10-09 | 珀莱雅化妆品股份有限公司 | 一种具有美白紧致功效的纳米纤维膜及其制备方法 |
WO2021138031A1 (en) * | 2019-12-30 | 2021-07-08 | Rodan & Fields, Llc | Ppar agonist complex and methods of use |
Non-Patent Citations (2)
Title |
---|
JOSIE MARAN 公司: ""Smoothing Hand Treatment"", pages 1 - 5, Retrieved from the Internet <URL:http://www.gnpd.com/sinatra/recordpage/8725535/?utm_source=download&utm_medium=rtf> * |
彭冠杰,郭清泉: "《美白化妆品科学与技术》", 中国轻工业出版社, pages: 186 - 188 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115778880A (zh) * | 2023-02-01 | 2023-03-14 | 卡莱丽化妆品有限公司 | 一种脂质体及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60218125T2 (de) | Nicht therapeutisches Verfahren sowie therapeutische Anwendungen zur Hautdepigmentierung | |
WO2021017846A1 (zh) | 增强的抗衰老化妆品组合物 | |
CN110721104B (zh) | 一种美白霜及其制备方法 | |
WO2018196482A1 (zh) | 护肤化妆品组合物 | |
WO2021031750A1 (zh) | 混合的桦树汁及其在护肤化妆品组合物中的应用 | |
CN115154383B (zh) | 一种温和美白组合物及其美白面霜 | |
US11911498B2 (en) | Low pH skin care composition and methods of using the same | |
CN115400065A (zh) | 一种具有保湿、抗皱、抗衰、舒缓、修复多功效的护肤品组合物及其应用 | |
KR102067009B1 (ko) | No 활성 억제제, 이를 포함하는 항염증 제제, 이를 포함하는 화장품 및 이의 제조방법 | |
CN112587456B (zh) | 一种修护美白组合物及其制备方法 | |
CN103142435A (zh) | 多机理抑制酪氨酸酶活性的美白组合物及其产品 | |
CN116763702A (zh) | 一种淡化深层斑点的组合物及其制备方法与应用 | |
EP3370832B1 (fr) | Composition cosmétique ou dermatologique qui comprend un extrait de jania rubens et une huile essentielle d'immortelle et son utilisation | |
CN115463048A (zh) | 一种祛痘焕颜精华液及其制备方法 | |
EP1262169B1 (fr) | Composition pour le traitement des signes cutanés du vieillissement | |
EP3102181B1 (fr) | Complexe actif pour un produit cosmétique contre le vieillissement cutané | |
CN115068384A (zh) | 一种快速美白组合物及其应用 | |
JP5858654B2 (ja) | 白毛の予防・治療剤、非治療的な美容方法、エンドセリンレセプターb遺伝子発現促進剤及びmitf−m遺伝子発現促進剤 | |
CN115887336A (zh) | 用于皮肤的祛红组合物和化妆品 | |
JP2009298752A (ja) | 皮膚外用剤組成物 | |
CN114344202A (zh) | 一种抗衰老组合物、护肤品及化妆品 | |
CN117815095A (zh) | 一种具有舒缓修护作用的组合物及其制备方法 | |
JP5010582B2 (ja) | 少なくとも一のオキサゾリンを活性成分として含有する、色素消失用又は光沢化粧品組成物 | |
US20160089319A1 (en) | Actives for stimulating differentiation of keratinocytes to lighten hyperpigmented skin | |
CN112618422A (zh) | 复合美白组合物、制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |